

About This Handbook

This Handbook is the third edition of a resource originally produced well over a decade ago. The last edition proved to be a valuable and much sought after document. In the intervening years since the last edition of the Handbook was produced the alcohol and other drugs field has changed, expanded and progressed in many ways. Hence, this new version covers expanded territory (such as polydrug use and coexisting mental health problems) and newer topic areas (such as gambling). Effort was directed at producing a resource document that was both user-friendly and also captured up-to-date, empirically sound health and medical advice. The information contained in the Handbook reflects evidence-based perspectives that are seen to be of practical value to the clinician in their day-to-day practice.

This Handbook has been produced with a very broad target audience in mind. Largely it will cater for the professional alcohol and other drugs needs of non-specialist medical practitioners and nurses. But it is also designed to be a useful practical tool for a wide range of other health and human services workers including psychologists, social workers and counsellors. We also envisage that it will be of value and interest to groups such as teachers, community workers and those with wider roles such as health promotion.

As a 'Handbook' this resource provides only a general summary overview of key issues pertinent to each of the topics covered. Readers are encouraged to seek more in-depth information from the various resources, links and contacts cited throughout the Handbook. Finally, it is important to note that the alcohol and other drugs field is particularly dynamic. While knowledge in any field is by necessity 'provisional', this may be considered to be especially the case in the changing and evolving area of alcohol and other drugs. The reader is therefore encouraged to use this resource as an entry point to the complex phenomenon of drug using behaviour and the challenging world of problem resolution.

Professor Ann M Roche
Handbook Project Head
Director
National Centre for Education and Training on Addiction (NCETA)
Flinders University
June 2003

Acknowledgments

The production of this Handbook on alcohol and other drugs has involved the input, support and collaboration of many players and partners. The proposal for the Handbook came from the consortium that formed the Editorial Group, and this was largely formed at the instigation of Professor James Rankin. Professor Rankin is thanked for his enthusiasm and drive in getting this project off the ground. The other consortium members are thanked for their sound advice and support throughout the duration of the production of the Handbook. The consortium's Editorial Group included:

- Professor Ann Roche (Project Head)
- Associate Professor Robert Ali
- Professor Richard Mattick
- Professor Brian McAvoy
- Professor James Rankin

The Handbook also involved the input of a range of individuals and groups that are not immediately apparent and this included our Reference Group and the Royal Australian College of General Practitioners (RACGP) who assisted in the piloting of the draft version of the document.

In addition, we would like to gratefully acknowledge the feedback received from many colleagues who contributed to various parts and stages of the process. Without the input of all of the above the production of this third edition of the Handbook would not have been possible.

We gratefully acknowledge the generosity of the Centre for Addiction and Mental Health (CAMH) in Canada for allowing us access to their publication:

*Managing Alcohol, Tobacco and Other Drug Problems:
A Pocket Guide for Physicians and Nurses*

Illustrations by Simon Kneebone.

List of Contributors

A wide range of contributors, each experts in specific areas, were involved in the writing of this Handbook. Some authors contributed whole chapters, others wrote smaller parts that were subsequently worked into larger sections or chapters. The authors who contributed to the Handbook in various ways are listed below.

Assoc. Professor Steve Allsop	Dr John Litt
Dr Michael Baigent	Professor Brian McAvoy
Dr Amanda Baker	Ms Annie Madden
Professor Bob Batey	Professor Andrea Mant
Dr Maggie Brady	Ms Heather Proudfoot
Dr Jan Copeland	Dr Alison Reid
Dr Kate Dolan	Professor Ann Roche
Professor Andrew Gilbert	Ms Jodie Shoobridge
Dr Tony Gill	Professor Tim Stockwell
Dr Linda Gowing	Dr Maree Teesson
Dr Paul Haber	Dr Libby Topp
Ms Jennifer Holmes	Professor Greg Whelan
Assoc. Professor Gary Hulse	Professor Jason White
Dr Nicole Lee	Dr Adam Winstock
Dr Patrick Lenehan	Dr Alex Wodak
Dr Nick Lintzeris	Dr Chris Wurm

In addition to the authors and the overseeing Consortium, an important role was played by a team of NCETA staff who worked extensively on the editing of the Handbook to ensure its accuracy and consistency in terms of style and presentation. The final editorial team mainly comprised Dr Carolyn Edmonds, Jodie Shoobridge and Professor Ann Roche.

In addition, a broader technical team also worked in the production of the Handbook and this group included Laura Jackson, Niola Curtis, Veronica Freund, Jane Malyschko, Joanne McDonald, Jodie Pearce, Sue Rayner, Chelsea Todd and Pamela Wright.

Contents

Overview

About This Handbook	i
Acknowledgments	iii
List of Contributors	iv
Contents – Overview	v
Contents – Detailed	vii
Preface	xxi
PART 1: OVERVIEW AND INTRODUCTION	1
1. Overview and Introduction	3
2. General Principles of Management and Intervention	17
PART 2: THE DRUGS	29
3. Alcohol	31
4. Tobacco	59
5. Cannabis	73
6. Amphetamines	79
7. Ecstasy	95
8. Cocaine	105
9. Heroin and Other Opioids	119
10. Volatile Substances	137
11. Benzodiazepines	147
12. Other Drugs	157
PART 3: NON-MEDICAL INTERVENTIONS	165
13. Psychosocial Interventions	167
14. Alternative Therapies	177

PART 4: ISSUES FOR SPECIAL CONSIDERATION	183
15. Pregnancy and Drug Use	185
16. Surgery and Substance Use	193
17. Managing Chronic Pain	199
18. Coexisting Mental Illness	207
19. Injecting and Communicable Diseases	215
20. Drug Issues in Correctional Services	223
21. Health Professionals As Patients	229
22. Gambling	233
PART 5: APPENDICES AND GLOSSARY	239
A. NHMRC Alcohol Guidelines – Short- and Long-term Risk	241
B. Laboratory Markers for Alcohol-related Damage	243
C. AUDIT – Interview Version	245
D. AUDIT – Self-report Version	247
E. Tip Sheet for Reducing Alcohol Consumption	249
F. Alcohol Withdrawal Assessment Scale (CIWA–AR)	251
G. Alcohol Withdrawal Observation Chart	253
H. The Five ‘A’s	255
I. CREATE	259
J. Proforma for Decision Balance Worksheet	261
K. Hepatitis C Referral Checklist	263
Glossary	265

Contents

Detailed

PART 1: OVERVIEW AND INTRODUCTION	1
1. OVERVIEW AND INTRODUCTION	3
Types of Drugs and their Effects	4
Identifying Harms	4
<i>The drug</i>	4
<i>The individual</i>	4
<i>The environment</i>	4
Drug Usage	4
Alcohol	5
Tobacco	5
Other Drugs	5
Polydrug Use	5
Routes of Administration	6
Terminology	7
Definitions of Drug and Alcohol Problems	7
Hazardous Use	7
Harmful Use	7
Substance 'Abuse'	9
Substance Dependence	9
Standards of Care	10
Attitudes Towards Drug Users	10
Drug Users' Rights	10
Role of Health and Human Services Providers	10
Medical Practitioners and Nurses	10
Other Frontline Workers	11
Health Professionals' Role with Aboriginal and Torres Strait Islanders	12
Health Professionals' Role with Culturally and Linguistically Diverse Groups	12
Prevention and Treatment Strategies	14
Secondary Prevention	14
Interpreting and Translation	14
Resources	14
Other Special Needs Groups	14
References	15

2. GENERAL PRINCIPLES OF MANAGEMENT AND INTERVENTION	17
Harm Minimisation	17
Efficacy of Treatment	18
Early Recognition and Screening	18
Routine Enquiry About Alcohol and Drug Use	18
Screening Questionnaires	18
Biological Screening	19
Common Clinical Presentations	19
Assessment	19
Management of Low Level Problems	20
Psychosocial Interventions	21
Maintenance Pharmacotherapies	21
Pharmacotherapies for Alcohol Dependence	22
Acamprosate (Campral®)	22
Naltrexone (Revia®)	22
Disulfiram (Antabuse®)	22
Pharmacotherapies for Opioid Dependence	22
Buprenorphine	22
Methadone	22
Levoalphaacetylmethadol (LAAM)	22
Naltrexone (Revia®)	23
Withdrawal and Detoxification	23
Intoxication and Overdose	23
Coexisting Mental Health Problems	24
Drug Seeking	24
Clinical Features	24
Management	25
General Management Approaches	25
Readiness to Change	26
Resources	27
References	27

PART 2: THE DRUGS

29

3. ALCOHOL	31
Pharmacology	31
Absorption	31
Distribution	32
Metabolism	32
Patterns of Drinking	32
Benefits and Harms	32
Effects of Alcohol Consumption	33
Measuring Consumption: The ‘Standard Drink’	35
Identifying ‘At-risk’ Drinking Levels	35
Groups at High Risk for Alcohol-related Harm	35
<i>Young people (up to 18 years) and young adults (19–25 years)</i>	35
<i>People with mental health problems</i>	37
<i>Unborn children</i>	37
<i>Women</i>	37
<i>Occupational groups</i>	37
Identifying Harms	37
<i>The drug</i>	37
<i>The individual</i>	37
<i>The environment</i>	38
Alcohol Assessment	39
Early Recognition of Alcohol-related Problems	39
Four Key Assessment Steps	39
Screening for Alcohol Use	42
Invasive Measures	42
<i>Estimating BAC (Blood Alcohol Concentration)</i>	42
Non-invasive Measures	42
<i>CAGE</i>	42
<i>The AUDIT</i>	43
Brief Interventions	43
Alcohol Intoxication	44
Acute Alcohol Intoxication	44
Assessment of Alcohol Intoxication	44
Alcohol Dependence	46
Alcohol Withdrawal	46
General Guidelines for Alcohol Withdrawal Management	46
<i>Home withdrawal management</i>	47
Psychosocial and Physical Support During Alcohol Withdrawal	47
Pharmacological Management of Alcohol Withdrawal	48
After-care	50
Self-help Resources	50
Self-help Groups	50
Pharmacotherapies to Reduce Relapse/Promote Abstinence	50

3. ALCOHOL (continued)	50
Alcohol-related Brain Injury (ARBI)	50
Wernicke–Korsakoff’s Syndrome	51
Resources	54
References	56
4. TOBACCO	59
Pharmacology	59
At-risk Groups	60
Detection and Assessment	60
Adverse Physical and Psychological Effects	60
Acute System Effects	60
Local Toxic Effects	60
Chronic System Toxicity	60
<i>Cardiovascular disease</i>	60
<i>Respiratory</i>	60
<i>Cancer and malignancies</i>	61
<i>Gastrointestinal</i>	61
<i>Complications related to pregnancy and reproduction</i>	61
<i>Degenerative disease</i>	61
<i>Injuries and trauma</i>	61
<i>Environmental tobacco smoke (ETS)</i>	61
Nicotine Dependence and Withdrawal	61
<i>Nicotine dependence</i>	61
<i>Nicotine withdrawal effects</i>	62
<i>Psychological effects</i>	62
Social Complications	62
Smoking Cessation Strategies	63
The Benefits of Quitting	63
Barriers to Assisting Smokers	63
Smoking Cessation Guidelines	63
<i>The Five ‘A’s</i>	65
<i>CREATE</i>	65
<i>Decision Balance Worksheet</i>	65
Pharmacotherapies	66
<i>Nicotine replacement therapies (NRTs)</i>	66
<i>Bupropion (Zyban®)</i>	66
Other Strategies	68
Resources	69
References	72

5. CANNABIS	73
Pharmacology	73
Common Names	73
Routes of Administration	74
Physical and Psychosocial Complications	74
Acute Effects	74
Negative Acute Effects	74
Harms Associated with Chronic Use	74
High Risk Groups	74
Management and Intervention Strategies	75
Assessment	75
Respiratory Function	75
Cardiovascular	75
Detection by Urine Analysis	75
Psychosocial Interventions	75
Tolerance, Dependence and Withdrawal	76
Management and Intervention	76
References	77
6. AMPHETAMINES	79
Pharmacology	79
Distribution	80
Metabolism	80
Availability and Quality	80
Patterns of Use	81
Routes of Administration	81
Physical and Psychological Effects	81
Acute Physical and Psychological Effects	81
Long-term Physical Effects	81
Long-term Psychological Effects	84
Amphetamine-related Harms	84
Management and Intervention Strategies	85
Acute Adverse Effects: Uncomplicated Intoxication	85
Acute Adverse Effects: Intoxication with Complications	86
Using and Stopping Amphetamines	87
Identification and Detection of Amphetamine Use and Related Problems	87
Assessment	88
Withdrawal	89
Non-pharmacological Management of Withdrawal	89
<i>Inpatient withdrawal management</i>	89
Pharmacotherapies for Managing Withdrawal and Relapse	90
Intervention Strategies Post-withdrawal	90
Harm Reduction Measures	91
Resources	92
References	93

7. ECSTASY	95
Pharmacology	95
Patterns of Use	96
Physical and Psychosocial Complications	96
Physical Effects of Ecstasy	96
<i>Hyperthermia</i>	96
<i>Hyponatraemia ('water intoxication')</i>	97
<i>Dose–response relationship</i>	98
<i>Liver damage</i>	98
Neurotoxicity	98
Psychological Effects and Complications	99
Management and Intervention Strategies	99
Strategies for Different Levels of Use	99
<i>Acute adverse effects</i>	99
Treatment for Ecstasy Use	99
<i>Pharmacological interventions</i>	99
<i>Non-pharmacological interventions</i>	99
References	101
8. COCAINE	105
Pharmacology	105
Australian Street Names	106
Prevalence and Patterns of Use	106
Availability	106
Routes of Administration	106
Bingeing	107
Types of Users	107
Polydrug Use	107
Snorters	107
Injectors	107
Cocaine and Alcohol	107
Effects of Cocaine	108
Factors Influencing the Effects	108
Desired Effects	108
Other Acute Effects of Low Doses	108
Acute Effects of High Doses ('Toxic Reactions')	108
Effects of Chronic Use	109
Physical and Psychosocial Complications	109
Physical Problems Relating to Route of Administration	109
<i>Intranasal users</i>	109
<i>Injecting users</i>	109
Other Physical Problems	109
Cocaine-related Death	109
Psychological Problems	109
Social Problems	109
Cocaine Dependence	110

8. COCAINE (continued)	
Cocaine Withdrawal Syndrome	110
Foetal Effects	110
Management and Intervention Strategies	111
Clinical Screening	111
<i>Acute toxic reactions</i>	111
Chronic Cocaine Use	111
Treatment of Toxic Reactions	111
Management of Withdrawal	112
Treatment of Cocaine Dependence	112
<i>Pharmacotherapy</i>	112
<i>Cognitive-behavioural therapy</i>	112
<i>Contingency management</i>	113
<i>Enhancement of psychosocial skills</i>	113
<i>Acupuncture</i>	113
<i>General approaches</i>	113
<i>Comorbid disorders</i>	113
<i>Readiness to change</i>	114
References	115
9. HEROIN AND OTHER OPIOIDS	119
Patterns of Heroin Use	119
Opioid Drugs	119
Heroin	119
Morphine	120
Methadone	120
Buprenorphine (Subutex®)	121
Naltrexone	122
Tolerance	123
Withdrawal	123
Dependent Heroin Use	123
The Dependence Syndrome	123
Natural History of Dependent Heroin Use	123
Features of Dependent Heroin Use in Australia	124
Harms Associated with Heroin Use	124
Overdose	124
Harms Related to Injecting	124
Psychological Harms	125
Social and Community Harms	125
Management and Intervention Strategies	125
Withdrawal Services	125
Objectives	125
Key Components	125
<i>Assessment</i>	125
<i>Setting</i>	125
<i>Supportive care</i>	125

9. HEROIN AND OTHER OPIOIDS (continued)	
<i>Frequent monitoring and review</i>	126
<i>Medication</i>	126
Medication Regimes for Opioid Withdrawal	127
Post-withdrawal Interventions	130
<i>Psychosocial interventions</i>	130
<i>Outpatient counselling</i>	130
<i>Therapeutic communities</i>	130
<i>Self-help groups</i>	131
Naltrexone Treatment	131
<i>Clinical aspects</i>	131
<i>Adverse events</i>	131
<i>Outcomes associated with naltrexone treatment</i>	131
Substitution Maintenance Treatment	
with Methadone or Buprenorphine	131
Rationale, Objectives and Outcomes	131
Delivering Substitution Treatment in Australia	132
Problems with Maintenance Substitution Treatment	133
Principles of Safe and Effective Methadone/Buprenorphine Treatment	133
Resources	134
References	135
10. VOLATILE SUBSTANCES	137
Commonly Used Volatile Substances	137
Modes of Administration	138
Prevalence	138
Appeal	139
Physical Complications	139
Acute Effects	139
Negative Acute Effects	139
Effects at Higher Doses	139
Specific Physical Effects	139
<i>Central nervous system</i>	139
<i>Maternal and neonatal</i>	140
<i>Heart</i>	140
<i>Lung</i>	140
<i>Kidneys, liver and bone marrow</i>	140
Other Morbidity and Mortality	140
Psychosocial Complications	140
Management and Intervention Strategies	141
Detection and Assessment	141
Intoxication	141
Experimental, Recreational and Chronic Use	141
Primary Prevention Strategies	143
Resources	144
References	145

11. BENZODIAZEPINES	147
Pharmacology	147
Absorption	147
Distribution	148
Metabolism	148
Patterns of Use	148
Effects of Benzodiazepines	148
Short-term Effects	148
Long-term Effects	149
Uses and Problems	149
High Risk Groups	149
Prescribing Benzodiazepines	150
Rational Use of Benzodiazepines	150
Precautions	150
Drug Interactions	150
Use in Management of Anxiety and Insomnia	150
Management and Intervention Strategies	151
Reviewing Benzodiazepines in Long-term Users: A Staged Approach	151
Dependence and Withdrawal	152
Aged Care Residential Facilities	153
Benzodiazepine Misuse	153
Habitual Drug Users ('Doctor Shoppers')	153
Drug Dependent Patients	153
References	155
12. OTHER DRUGS	157
Hallucinogens	157
Physical and Psychological Effects	158
Management and Intervention	158
Party Drugs	158
GHB	159
Ketamine	159
Anabolic Steroids	160
Over The Counter Drugs	161
Non-prescription Medication	161
<i>Analgesics</i>	161
<i>Antihistamines</i>	161
<i>Sympathomimetics</i>	161
<i>Cough suppressants</i>	162
Injecting Drug Users	162
<i>Other</i>	162
References	163

PART 3: NON-MEDICAL INTERVENTIONS	165
13. PSYCHOSOCIAL INTERVENTIONS	167
Patient Readiness — A Model of the Process of Change	168
Pre-contemplation Stage	168
Contemplation Stage	169
Preparation Stage	169
Action Stage	169
Maintenance Stage	169
Clinical Strategies	169
Patient-centred Approach	169
Decision Balance	169
Building A Therapeutic Alliance	169
<i>Empathy and reflective listening</i>	170
<i>Using open ended questions</i>	171
<i>Reflective listening</i>	171
<i>Summarising</i>	171
<i>Roadblocks to empathy</i>	171
Motivational Interviewing	172
Brief Motivational Interviewing	173
Problem Solving	174
Goal Setting	174
Relapse Prevention	175
Quality of Life	175
References	176
14. ALTERNATIVE THERAPIES	177
Evidence of Effectiveness	177
Acupuncture	178
Hypnosis	179
Conclusions	179
References	180

PART 4: ISSUES FOR SPECIAL CONSIDERATION	183
15. PREGNANCY AND DRUG USE	185
Assessment	185
Information on Alcohol and Drug Effects	187
Alcohol	187
Tobacco	188
Cannabis	189
Heroin	189
Psychostimulants — Amphetamines and Cocaine	190
Ecstasy	190
Neonatal Abstinence Syndrome (NAS)	191
Child Protection	191
References	192
16. SURGERY AND SUBSTANCE USE	193
Tobacco	194
Alcohol	194
Alcohol and Post-operative Morbidity	194
Peri-operative Management of Alcohol-related Complications	195
Opioids	196
Management Strategies	197
Benzodiazepines	197
Stimulant Use	197
References	198
17. MANAGING CHRONIC PAIN	199
Acute and Chronic Pain	199
Assessment and Pain Management in Drug Users	200
Screening for Substance Dependence	201
Alternative Options in Management	201
Dependence and Tolerance	202
Preventing Drug Dependence in Patients with Chronic Non-malignant Pain	202
Principles of Pain Management in Opioid Dependent Patients	203
<i>Methadone maintenance</i>	203
<i>Buprenorphine</i>	204
<i>Terminal illness</i>	204
The Potential for Adverse Interactions	204
The Patient–Clinician Relationship	205
Resources	206

18. COEXISTING MENTAL ILLNESS	207
Epidemiology	207
Terminology	208
Some Specific Associations	208
From a Drugs Perspective	209
From a Mental Health Perspective	209
Management	210
What Works?	210
Principles of Care	210
Assessment and Management	210
Harm Minimisation	211
Resources	212
References	213
19. INJECTING AND COMMUNICABLE DISEASES	215
Infective Problems Associated with Injecting Drug Use	216
Blood Borne Communicable Diseases	216
Hepatitis C	216
Testing for HCV	216
Natural History	217
Assessing Patients for Treatment	217
Antiviral Therapy	217
Managing Patients who have Failed Therapy or are Ineligible for Treatment	217
Liver Transplantation in HCV	217
Prevention of HCV	217
Alcohol and HCV	218
Hepatitis B	218
Testing for HBV	218
Natural History	218
Treatment of HBV	218
Hepatitis D	219
Human Immunodeficiency Virus	219
Testing for HIV	219
Treatment of HIV	219
Prevention	219
Effect of HIV on IDU Problems	219
HTLV/III	220
Resources	221

20. DRUG ISSUES IN CORRECTIONAL SERVICES	223
Patterns of Drug Use Among Prisoners	223
History of Imprisonment and Prevalence of Injecting	224
Prevalence and Transmission of Blood Borne Viral Infections	224
Interventions to Reduce Risk Behaviour and Transmission	224
Bleach Programs	225
Condoms	225
Methadone Maintenance Treatment	225
Syringe Exchange Schemes in Prison	225
References	227
21. HEALTH PROFESSIONALS AS PATIENTS	229
Treating a Health Professional with a Drug or Alcohol Problem	230
Dealing with a Colleague with a Drug or Alcohol Problem	230
Registering Authorities	230
The Steps to Take	231
Being a Health Professional with a Drug or Alcohol Problem	231
22. GAMBLING	233
Problem Gambling	233
Identifying Problem Gamblers	234
Presentation of Problem Gamblers	234
Treatment/Referral Options	236
References	237

PART 5: APPENDICES AND GLOSSARY **239**

A. NHMRC Alcohol Guidelines – Short- and Long-term Risk	241
B. Laboratory Markers for Alcohol-related Damage	243
C. AUDIT – Interview Version	245
D. AUDIT – Self-report Version	247
E. Tip Sheet for Reducing Alcohol Consumption	249
F. Alcohol Withdrawal Assessment Scale (CIWA-AR)	251
G. Alcohol Withdrawal Observation Chart	253
H. The Five ‘A’s	255
I. CREATE	259
J. Proforma for Decision Balance Worksheet	261
K. Hepatitis C Referral Checklist	263
Glossary	265

